Ascendiant cuts Cerenome price target to $43
Ascendiant Capital cut its Cerenome price target to $43.00 per share from $57.00, while maintaining a Buy rating, per Benzinga via TradingView.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.